# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price ...
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate o...
HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price ...
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate o...
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company...
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary A...